Prevalence of cardiac fibrosis and infiltrative cardiomyopathy in patients with advanced conduction system disease
Abstract Background Conduction system disease may represent an early manifestation of underlying structural heart disease, including infiltrative disorders. Timely diagnosis of underlying cardiomyopathy has significant implications for clinical management, guiding both disease‐modifying medical ther...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Journal of Arrhythmia |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/joa3.70109 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221919769886720 |
|---|---|
| author | Jeremy William Haider Muthana Joseph Hogarty Andrew Taylor James L. Hare Justin Mariani Hitesh Patel Geoff Wong Dion Stub David M. Kaye Sandeep Prabhu Peter M. Kistler Aleksandr Voskoboinik |
| author_facet | Jeremy William Haider Muthana Joseph Hogarty Andrew Taylor James L. Hare Justin Mariani Hitesh Patel Geoff Wong Dion Stub David M. Kaye Sandeep Prabhu Peter M. Kistler Aleksandr Voskoboinik |
| author_sort | Jeremy William |
| collection | DOAJ |
| description | Abstract Background Conduction system disease may represent an early manifestation of underlying structural heart disease, including infiltrative disorders. Timely diagnosis of underlying cardiomyopathy has significant implications for clinical management, guiding both disease‐modifying medical therapy and decisions around device implantation. Objective We sought to investigate the utility of cardiac magnetic resonance imaging (CMR) in patients with conduction system disease and preserved LV function on echocardiography. Methods We evaluated all patients undergoing CMR between 2005 and 2023 at our institution for the investigation of advanced conduction system disease (complete heart block, Mobitz II block, or bifascicular block). We excluded patients with known systolic heart failure (LVEF<50%) prior to CMR. We evaluated the prevalence of CMR‐detected myocardial fibrosis and infiltrative cardiomyopathy in this cohort. Results One hundred nineteen patients were identified (mean age 49 ± 15 years, 52% male). Complete heart block was the most common indication (50%), followed by bifascicular block (27%) and Mobitz II block (23%). Mean LVEF on echocardiography prior to CMR was 60.0 ± 3.1%. CMR‐detected late gadolinium enhancement (LGE) was present in 32/119 patients (26.9%). Cardiac sarcoid was the most common final diagnosis (n = 19, 16%), of whom only five (26%) had known extracardiac sarcoid prior to CMR. Cardiac fibrosis was observed in a similar proportion of patients across the three subtypes of conduction disease studied (p = 0.47). Conclusion Cardiac fibrosis is present in a substantial proportion of patients undergoing CMR for the investigation of conduction disease, even when LV function appears preserved on echocardiography. Cardiac MRI may be an important adjunctive tool for the investigation of conduction disease, particularly in younger patients. |
| format | Article |
| id | doaj-art-ada7782d97664047be90ec21faf87e79 |
| institution | Kabale University |
| issn | 1880-4276 1883-2148 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Arrhythmia |
| spelling | doaj-art-ada7782d97664047be90ec21faf87e792025-08-26T10:38:54ZengWileyJournal of Arrhythmia1880-42761883-21482025-08-01414n/an/a10.1002/joa3.70109Prevalence of cardiac fibrosis and infiltrative cardiomyopathy in patients with advanced conduction system diseaseJeremy William0Haider Muthana1Joseph Hogarty2Andrew Taylor3James L. Hare4Justin Mariani5Hitesh Patel6Geoff Wong7Dion Stub8David M. Kaye9Sandeep Prabhu10Peter M. Kistler11Aleksandr Voskoboinik12The Alfred Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaRoyal Melbourne Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaThe Alfred Hospital Melbourne AustraliaAbstract Background Conduction system disease may represent an early manifestation of underlying structural heart disease, including infiltrative disorders. Timely diagnosis of underlying cardiomyopathy has significant implications for clinical management, guiding both disease‐modifying medical therapy and decisions around device implantation. Objective We sought to investigate the utility of cardiac magnetic resonance imaging (CMR) in patients with conduction system disease and preserved LV function on echocardiography. Methods We evaluated all patients undergoing CMR between 2005 and 2023 at our institution for the investigation of advanced conduction system disease (complete heart block, Mobitz II block, or bifascicular block). We excluded patients with known systolic heart failure (LVEF<50%) prior to CMR. We evaluated the prevalence of CMR‐detected myocardial fibrosis and infiltrative cardiomyopathy in this cohort. Results One hundred nineteen patients were identified (mean age 49 ± 15 years, 52% male). Complete heart block was the most common indication (50%), followed by bifascicular block (27%) and Mobitz II block (23%). Mean LVEF on echocardiography prior to CMR was 60.0 ± 3.1%. CMR‐detected late gadolinium enhancement (LGE) was present in 32/119 patients (26.9%). Cardiac sarcoid was the most common final diagnosis (n = 19, 16%), of whom only five (26%) had known extracardiac sarcoid prior to CMR. Cardiac fibrosis was observed in a similar proportion of patients across the three subtypes of conduction disease studied (p = 0.47). Conclusion Cardiac fibrosis is present in a substantial proportion of patients undergoing CMR for the investigation of conduction disease, even when LV function appears preserved on echocardiography. Cardiac MRI may be an important adjunctive tool for the investigation of conduction disease, particularly in younger patients.https://doi.org/10.1002/joa3.70109cardiac MRIconduction diseasefibrosisinfiltrative cardiomyopathy |
| spellingShingle | Jeremy William Haider Muthana Joseph Hogarty Andrew Taylor James L. Hare Justin Mariani Hitesh Patel Geoff Wong Dion Stub David M. Kaye Sandeep Prabhu Peter M. Kistler Aleksandr Voskoboinik Prevalence of cardiac fibrosis and infiltrative cardiomyopathy in patients with advanced conduction system disease Journal of Arrhythmia cardiac MRI conduction disease fibrosis infiltrative cardiomyopathy |
| title | Prevalence of cardiac fibrosis and infiltrative cardiomyopathy in patients with advanced conduction system disease |
| title_full | Prevalence of cardiac fibrosis and infiltrative cardiomyopathy in patients with advanced conduction system disease |
| title_fullStr | Prevalence of cardiac fibrosis and infiltrative cardiomyopathy in patients with advanced conduction system disease |
| title_full_unstemmed | Prevalence of cardiac fibrosis and infiltrative cardiomyopathy in patients with advanced conduction system disease |
| title_short | Prevalence of cardiac fibrosis and infiltrative cardiomyopathy in patients with advanced conduction system disease |
| title_sort | prevalence of cardiac fibrosis and infiltrative cardiomyopathy in patients with advanced conduction system disease |
| topic | cardiac MRI conduction disease fibrosis infiltrative cardiomyopathy |
| url | https://doi.org/10.1002/joa3.70109 |
| work_keys_str_mv | AT jeremywilliam prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT haidermuthana prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT josephhogarty prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT andrewtaylor prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT jameslhare prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT justinmariani prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT hiteshpatel prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT geoffwong prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT dionstub prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT davidmkaye prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT sandeepprabhu prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT petermkistler prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease AT aleksandrvoskoboinik prevalenceofcardiacfibrosisandinfiltrativecardiomyopathyinpatientswithadvancedconductionsystemdisease |